Abstract
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of >10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10−8; 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Eeles, R. et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 11, 18–31 (2014).
Eeles, R.A. et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45, 385–391 (2013).
Park, J.H. et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat. Genet. 42, 570–575 (2010).
Eeles, R.A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316–321 (2008).
Gudmundsson, J. et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122–1126 (2009).
Schumacher, F.R. et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. 20, 3867–3875 (2011).
Thomas, G. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310–315 (2008).
Cheng, I. et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol. Biomarkers Prev. 21, 2048–2058 (2012).
Haiman, C.A. et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 7, e1001387 (2011).
Duggan, D. et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl. Cancer Inst. 99, 1836–1844 (2007).
Haiman, C.A. et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet. 43, 570–573 (2011).
Cook, M.B. et al. A genome-wide association study of prostate cancer in West African men. Hum. Genet. 133, 509–521 (2014).
Akamatsu, S. et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat. Genet. 44, 426–429 (2012).
Takata, R. et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42, 751–754 (2010).
Sun, J. et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 69, 10–15 (2009).
Hedstrom, L. Serine protease mechanism and specificity. Chem. Rev. 102, 4501–4524 (2002).
Morris, D.S., Tomlins, S.A., Montie, J.E. & Chinnaiyan, A.M. The discovery and application of gene fusions in prostate cancer. BJU Int. 102, 276–282 (2008).
Falchi, M. et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915–919 (2009).
Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15–21 (1994).
Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41, 899–904 (2009).
Stacey, S.N. et al. New common variants affecting susceptibility to basal cell carcinoma. Nat. Genet. 41, 909–914 (2009).
Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42, 504–507 (2010).
Wrensch, M. et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905–908 (2009).
Timofeeva, M.N. et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum. Mol. Genet. 21, 4980–4995 (2012).
Tikhmyanova, N., Little, J.L. & Golemis, E.A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 67, 1025–1048 (2010).
Loikkanen, I. et al. Myosin VI is a modulator of androgen-dependent gene expression. Oncol. Rep. 22, 991–995 (2009).
Puri, C. et al. Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. Oncogene 29, 188–200 (2010).
Wei, S., Dunn, T.A., Isaacs, W.B., De Marzo, A.M. & Luo, J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 68, 1387–1395 (2008).
Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353–361 (2013).
Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11, 134 (2010).
Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
Hazelett, D.J. et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 10, e1004102 (2014).
Thurman, R.E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75–82 (2012).
Coetzee, S.G., Rhie, S.K., Berman, B.P., Coetzee, G.A. & Noushmehr, H. FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs. Nucleic Acids Res. 40, e139 (2012).
Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390–394 (2011).
Tan, P.Y. et al. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol. Cell. Biol. 32, 399–414 (2012).
Andreu-Vieyra, C. et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol. Cell. Biol. 31, 4648–4662 (2011).
Sharma, N.L. et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23, 35–47 (2013).
Jeggari, A., Marks, D.S. & Larsson, E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 28, 2062–2063 (2012).
Wang, J. et al. Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res. 22, 1798–1812 (2012).
Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633–641 (2013).
Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 321, 129–135 (1989).
Irizarry, R.A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
Summersgill, B., Clark, J. & Shipley, J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat. Protoc. 3, 220–234 (2008).
Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882–888 (2007).
Saramäki, O.R. et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 14, 3395–3400 (2008).
Acknowledgements
A full list of acknowledgments is detailed in the Supplementary Note.
Author information
Authors and Affiliations
Consortia
Contributions
A.H., R.A.E., Z.K.-J., D.F.E., B.E.H., S.J.C., S.I.B., P. Kraft, F.W., H.N. and M.B.C. designed the study. C.A.H., Z.K.-J., A.A.A.O. and R.A.E. wrote the manuscript. A.A.A.O., F.S., Y.H., Z.W., P.W., C. Chen, E.S., D.L., K.R., T.D., S.J.-L. and K.L.P. performed the statistical analysis. D.O.S. and D.V.C. provided statistical support. D.J. Hazelett, A. Stram, K.P., X.S., G.A.C., Q.L. and M.L.F. provided bioinformatics support as well as functional annotation and QTL data. L.C.P., K.P., L.X., L.B. and M.T. conducted the genotyping and sequencing. S.B., C.G. and M. Ahmed managed the PRACTICAL and COGS database. K.G. and M.G. managed the UKGPCS database. The following authors provided samples and/or data to the study and commented on the manuscript: J.T., T.V., K.A.L., K.-T.K., S.K.M., D.J.S., S.H., B.K., A.H.C., A.P.C., D.W., W.K., A.W.P. and E.M.G. L.N.K., L.L.M. and B.E.H. are principal investigators of the MEC. J.X. and S.L.Z. are principal investigators of NCPCS. R.C.T., T.J.K., A. Siddiq and F.C. are EPIC investigators. E.R. is the principal investigator of EPIC. A. Takahashi, M.K. and H.N. are principal investigators of BBJ. J.L.S. is the principal investigator of KCPCS; S.K. coordinated data collection. V.L.S. and W.R.D. are investigators and S.M.G. is the principal investigator of CPSII. S.S.S. and C.P. are principal investigators of the MDA prostate cancer studies. S.L., D.J. Hunter, P. Kraft, L.M., E.L.G., J.M. and M. Stampfer are coinvestigators of the Harvard cohorts and BPC3. H.G. is principal investigator of CAPS and STHLM1. M. Aly and F.W. are investigators of CAPS. W.B.I. is the principal investigator of the IPCG study. A.S.K. is the principal investigator of WUGS. E.M.J. is the principal investigator of SFPCS. S.A.I. is the principal investigator of LAAPC. R.A.K. and A.B.M. are investigators of DCPC. W.B., L.B.S. and W.Z. are principal investigators of SCCS. D.A. and J.V. are principal investigators and S.W. is the study coordinator of ATBC. B.N., J. Carpten, C.L., S.-Y.W. and A. Hennis are principal investigators of PCBP. B.A.R. and C.N.-D. are principal investigators of GECAP. J.S.W. and G.C. are principal investigators of CaP Genes. D.S. is the program officer of GAME-ON. P.J.G., E.A.K., A.W.H. and L.C. are investigators of SELECT. F.C.H., J.D. and D.E.N. are principal investigators of ProtecT. E.D.Y., Y.T., R.B.B., A.A.A., E.T., A. Truelove, S.N. and A.W.H. are investigators of the Ghana Prostate Study. S.J.C., S.I.B., R.N.H., M.J.M., M.Y., C.C.C., A. Hutchinson and K.Y. are investigators of PLCO. M.R.T. is the principal investigator and P. Paulo and S.M. are investigators of IPO-Porto. J.B., J. Clements and A. Spurdle are principal investigators of QLD. R.K. and C. Slavov are the principal investigators and V.M. is an investigator of PCMUS. J.P., T.S. and H.-Y.L. are the investigators of the MOFFITT study. L.C.-A. is the principal investigator of the Utah study. C. Cybulski is the principal investigator of the Poland study. S.N.T. is the principal investigator of the Mayo study. P. Pharoah and N.P. are investigators of SEARCH. C.M. is the principal investigator of ULM; M.L., K.H. and A.E.R. are investigators of ULM. M.W., S.F.N., B.G.N., P. Klarskov, M.A.R. and P.I. are the principal investigators of CPCS1 and CPCS2. T.W., A.A. and T.L.J.T. are investigators and J.S. is the principal investigator of TAMPERE. K.M. is a UKGPCS investigator. H.B. is the principal investigator, A.K.D. prepared the data and C. Stegmaier coordinated the data collection of the ESTHER study. G.G.G. and G.S. are the principal investigators of MCCS; M. Southey is an investigator and H.P., A.M. and A.M.K. are principal investigators of the PPF-UNIS study.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
A complete list of all consortia members is provided in the Supplementary Note.
A complete list of all consortia members is provided in the Supplementary Note.
A complete list of all consortia members is provided in the Supplementary Note.
A complete list of all consortia members is provided in the Supplementary Note.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 and Supplementary Note. (PDF 6302 kb)
Supplementary Tables 1–17
Supplementary Tables 1–17. (XLSX 113 kb)
Rights and permissions
About this article
Cite this article
Al Olama, A., Kote-Jarai, Z., Berndt, S. et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46, 1103–1109 (2014). https://doi.org/10.1038/ng.3094
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3094
This article is cited by
-
PQBP5/NOL10 maintains and anchors the nucleolus under physiological and osmotic stress conditions
Nature Communications (2023)
-
Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence
Scientific Reports (2022)
-
Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer
Clinical and Translational Oncology (2022)
-
Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort
Prostate Cancer and Prostatic Diseases (2021)
-
Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
Prostate Cancer and Prostatic Diseases (2021)